Kura Oncology, Inc. (KURA)
10.10
-0.30
(-2.84%)
USD |
NASDAQ |
Oct 13, 09:44
Kura Oncology Free Cash Flow (Quarterly) : -63.20M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -63.20M |
| March 31, 2026 | -85.98M |
| December 31, 2025 | 114.95M |
| September 30, 2025 | -83.19M |
| June 30, 2025 | -30.24M |
| March 31, 2025 | -72.22M |
| December 31, 2024 | 268.76M |
| September 30, 2024 | -43.44M |
| June 30, 2024 | -42.55M |
| March 31, 2024 | -48.93M |
| December 31, 2023 | -34.32M |
| September 30, 2023 | -29.05M |
| June 30, 2023 | -25.71M |
| March 31, 2023 | -35.91M |
| December 31, 2022 | -26.54M |
| September 30, 2022 | -21.39M |
| June 30, 2022 | -30.52M |
| March 31, 2022 | -32.23M |
| December 31, 2021 | -23.47M |
| September 30, 2021 | -25.32M |
| June 30, 2021 | -28.36M |
| March 31, 2021 | -28.55M |
| December 31, 2020 | -18.58M |
| Date | Value |
|---|---|
| September 30, 2020 | -17.63M |
| June 30, 2020 | -15.45M |
| March 31, 2020 | -20.33M |
| December 31, 2019 | -13.93M |
| September 30, 2019 | -12.14M |
| June 30, 2019 | -14.43M |
| March 31, 2019 | -14.25M |
| December 31, 2018 | -10.21M |
| September 30, 2018 | -13.00M |
| June 30, 2018 | -12.59M |
| March 31, 2018 | -12.85M |
| December 31, 2017 | -7.474M |
| September 30, 2017 | -6.235M |
| June 30, 2017 | -6.11M |
| March 31, 2017 | -8.622M |
| December 31, 2016 | -6.738M |
| September 30, 2016 | -5.472M |
| June 30, 2016 | -5.825M |
| March 31, 2016 | -7.314M |
| December 31, 2015 | -5.62M |
| September 30, 2015 | -4.452M |
| June 30, 2015 | -3.784M |
| March 31, 2015 | -4.133M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Fortress Biotech, Inc. | -59.36M |
| Spero Therapeutics, Inc. | -5.355M |
| Gossamer Bio, Inc. | -41.39M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |